New Horizons in Kidney Health: Focal Segmental Glomerulosclerosis Drugs Market Forecast 2024

The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $14.43 billion in 2023 to $15.77 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support.

The focal segmental glomerulosclerosis drugs market size is expected to see strong growth in the next few years. It will grow to $22.41 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.

Market Overview -
Focal segmental glomerulosclerosis (FSGS) is a rare type of kidney disease that causes scarring in the kidneys' filters. Focal segmental glomerulosclerosis (FSGS) drugs refer to medications used to treat and manage the progression of the disease.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp

Elevated Prevalence Of Kidney Infections Fueling Growth In The Focal Segmental Glomerulosclerosis (FSGS) Drugs Market
The rising prevalence of kidney infections is expected to propel the growth of the focal segmental glomerulosclerosis (FSGS) drugs market going forward. A kidney infection, or pyelonephritis, is a severe type of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, which are used to treat kidney diseases, offer several benefits in managing the condition and improving kidney function by reducing proteinuria, slowdowns the progression of kidney damage, and helping the patients suffering from kidney diseases with improved quality of life. For instance, in July 2022, according to the Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, around 15%, or 37 million people in the US, were affected by kidney disease. The prevalence among individuals aged 45-64 is 12% and the prevalence among people between 18 and 44 was 6% in 2021. Therefore, the rising prevalence of kidney infections drives the focal segmental glomerulosclerosis (FSGS) market.

Competitive Landscape -
Major players in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.

Introduction Of Novel Drugs, Gaining FDA Approval, And Orphan Drug Designation
Major companies operating in the focal segmental glomerulosclerosis (FSGS) market are increasingly focusing on product development and innovation to provide reliable products to their customers and strengthen their market position. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched FILSPARI, for focal segmental glomerulosclerosis (FSGS), which was approved by the Food and Drug Administration (FDA), a US-based federal agency. It is an oral medicine for treating IgA nephropathy (IgAN). It is the first and only non-immunosuppressive treatment for lowering proteinuria in IgAN, a rare kidney disease. Additionally, FILSPARI has been given orphan drug designation in the United States and Europe for treating IgAN and focal segmental glomerulosclerosis (FSGS).

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Key Segments -
The focal segmental glomerulosclerosis drugs market covered in this report is segmented -

1) By Type: Losmapimod; SHP-627; Sparsentan; TM-5484; Other Types
2) By Treatment: Corticosteroids; Immunosuppressive Drugs; Angiotensin Converting Enzymes (ACE) Inhibitors; A.R. Blockers; Diuretics; Other Treatments
3) By Route of Administration: Oral; Parenteral
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.